NEW YORK – Daiichi Sankyo and AstraZeneca on Tuesday began a Phase II study of trastuzumab deruxtecan (Enhertu) in HER2-overexpressing advanced colorectal cancer.
NEW YORK – Daiichi Sankyo and AstraZeneca on Tuesday began a Phase II study of trastuzumab deruxtecan (Enhertu) in HER2-overexpressing advanced colorectal cancer.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.